特卡霉素 | 113167-61-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯类和类似物
• 中文名称: 特卡霉素
• 英文名称: Terdecamycin
• 英文别名: [(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-13-hydroxy-1,4,10,19-tetramethyl-17,18-dioxo-2-(2-oxopropanoylamino)-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-7-yl] 4-methylpiperazine-1-carboxylate
• CAS: 113167-61-6
• 化学式: C₃₁H₄₃N₃O₈
• 分子量: 585.7
• InChiKey: ZNZIMXXFUIVOSF-KHDAEWLFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  42
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  143
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  (-)-lankacidin C 以79%的产率得到
  参考文献：
  名称：

  MINAMIDA, ISAO;HASHIMOTO, NAOTO

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：ULTUPHARMA AB

  公开号：WO2017095319A1

  公开（公告）日：2017-06-08

  The invention relates to compounds of Formula (I), wherein the variables are as defined in the claims, which are useful in the treatment and/or prevention of bacterial infections in a subject. The invention further relates to the use of a compound of Formula (I) in the manufacture of a medicament, and medical devices when used in a method of treating or preventing a bacterial infection in a subject, and related aspects.

  该发明涉及式（I）的化合物，其中变量如权利要求中所定义，这些化合物在治疗和/或预防受试者的细菌感染方面是有用的。该发明还涉及使用式（I）的化合物制造药物，以及在治疗或预防受试者的细菌感染方法中使用时的医疗器械，以及相关方面。
• COMPOUNDS AND METHODS OF TREATING INFECTIONS
  申请人：GARG Sanjay

  公开号：US20160075665A1

  公开（公告）日：2016-03-17

  The invention provides compounds of Formula (I), and methods of treating or preventing a bacterial infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a bacterial infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a bacterial infection in a subject and to a medical device comprising the composition of the invention.

  本发明提供了化合物(I)的方法，以及使用化合物(I)治疗或预防受体内细菌感染的方法。本发明还提供了使用化合物(I)制造治疗受体内细菌感染的药物的方法。本发明还提供了在治疗或预防受体内细菌感染的方法中使用的医疗设备，以及包含本发明化合物的医疗设备。
• Compounds and methods of treating infections
  申请人：Neoculi Pty Ltd.

  公开号：US10253002B2

  公开（公告）日：2019-04-09

  The invention provides compounds of Formula I, and methods of treating or preventing a bacterial infection in a subject using a compound of Formula I. The invention also provides the use of a compound of Formula I in the manufacture of a medicament for the treatment of a bacterial infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a bacterial infection in a subject and to a medical device comprising the composition of the invention.

  本发明提供了式 I 化合物，以及使用式 I 化合物治疗或预防受试者细菌感染的方法。本发明还提供了式 I 化合物在制造治疗受试者细菌感染的药物中的用途。本发明进一步提供了一种用于治疗或预防受试者细菌感染方法中的医疗器械，以及包含本发明组合物的医疗器械。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• Compounds and methods of treating bacterial infections
  申请人：ULTUPHARMA AB

  公开号：US10471043B2

  公开（公告）日：2019-11-12

  The invention relates to compounds of Formula (I), wherein the variables are as defined in the claims, which are useful in the treatment and/or prevention of bacterial infections in a subject. The invention further relates to the use of a compound of Formula (I) in the manufacture of a medicament, and medical devices when used in a method of treating or preventing a bacterial infection in a subject, and related aspects.

  本发明涉及式(I)化合物，其中变量如权利要求中定义，该化合物可用于治疗和/或预防受试者的细菌感染。本发明进一步涉及式（I）化合物在制造药物中的用途，以及在治疗或预防受试者细菌感染的方法中使用时的医疗设备和相关方面。